Torsten Falk, PhD

Dr. Torsten Falk is a professor of neurology and pharmacology at The University of Arizona. He is director of the pre-clinical Parkinson's disease laboratory and received his PhD from the University of Hamburg, Germany. Dr. Falk has authored more than 35 peer-reviewed journal publications (h-index: 19, i-10-index: 29) and more than 140 peer-reviewed abstracts and conference presentations. He holds two patents, and his work has led to ongoing clinical trials testing a novel treatment for levodopa-induced dyskinesias. His work focuses on preclinical models to test novel pharmacological treatments for levodopa-induced dyskinesias, a major side effect of Parkinson’s disease (PD) treatment, and to develop glycopeptides for the treatment of PD. He is co-founder of Teleport Pharmaceuticals, LLC, a member of the grant review committee for the Parkinson's Foundation, a standing member of the NIH CNNT study section and an ad hoc reviewer for MJFF and the Parkinson’s UK Foundation.